Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1614 1628
This examiner grants 26% of resolved cases
Timothy P. Thomas is an examiner in Tech Center 1600 and Art Unit 1611, where he has overseen 912 resolved cases. His allowance rate of 26.3 is notably low, suggesting a very rigorous examination standard. This is accompanied by a median days to allowance of 1351, indicating a lengthy prosecution process for those applications that do reach a grant. The 912 resolved cases provide a robust data set for understanding these trends.
The interview lift of 38.0 is a critical statistic for practitioners. This high lift suggests that direct communication is a primary way to overcome rejections and move toward the 26.3 allowance rate. In the context of the 1351 days to allowance, an early interview could be a vital strategy for resolving issues more efficiently. The 912 resolved cases show that while the examiner maintains strict standards, the 38.0 interview lift offers a clear path for successful advocacy. Practitioners in Art Unit 1611 should prioritize verbal discussion to address the examiner concerns directly. Tech Center 1600 often involves complex subject matter, which may contribute to the 26.3 allowance rate and the 1351 days of pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19191890 | LOW-SORBING GLYBURIDE FORMULATION AND METHODS | Final Rejection | REMEDY PHARMACEUTICALS, INC. |
| 17614267 | COMPOSITION AND METHOD FOR ENHANCING SPORE GERMINATION AND BIOLOGICAL EFFICACY | Non-Final OA | DANSTAR FERMENT AG |
| 17633973 | ENZYME INHIBITORS | Non-Final OA | KALVISTA PHARMACEUTICALS LIMITED |
| 18581659 | METHOD OF TREATING ALZHEIMER'S DISEASE | Non-Final OA | Vector Vitale IP LLC |
| 17064443 | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF OBESITY | Final Rejection | Vector Vitale IP LLC |
| 16967990 | NOVEL PAENIBACILLUS POLYMYXA AND USES THEREOF | Final Rejection | VALAGRO S.P.A. |
| 16310857 | SYNERGISTIC ANTIMICROBIAL COMBINATIONS CONTAINING QUATERNARY AMMONIUM BIOCIDE | Final Rejection | LONZA, LLC |
| 18063886 | NUTRITIONAL FORMULA | Non-Final OA | Building Block Nutritionals, LLC |
| 17921540 | SOLID AND LIQUISOLID FORMULATIONS OF CORALLOPYRONIN A | Final Rejection | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN |
| 17917608 | COMPOSITION COMPRISING RESVERATROL | Final Rejection | GALENUS G.H. AG |
| 17995220 | THE USE OF DIFFUSION ENHANCING COMPOUNDS FOR TREATMENT OF VIRAL AND BACTERIAL INDUCED RESPIRATORY DISEASE | Non-Final OA | DIFFUSION PHARMACEUTICALS LLC |
| 17792863 | TOPICAL FORMULATION CONTAINING RAPAMYCIN | Final Rejection | NOBELPHARMA CO., LTD. |
| 17781006 | HIGH-STRENGTH MEDICAL FIBER COMPOSITE MATERIAL | Non-Final OA | CHANGZHOU INSTITUTE OF TECHNOLOGY |
| 17638868 | REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE | Final Rejection | SQUARE POWER LTD. |
| 17520763 | Photosensitive Dyes and Method of Using Said Dyes | Final Rejection | STRT LLC |
| 17279555 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NITM AND MEDICAL USE THEREOF | Final Rejection | SHENYANG XiNGQi PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy